PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update

Core Insights - PharmAla Biotech Holdings Inc. has successfully completed an international shipment of LaNeo™ MDMA to Yale University for a clinical trial focused on Borderline Personality Disorder [1][2] - This shipment follows a previous successful delivery to the University of Washington, indicating PharmAla's growing role in clinical research involving MDMA [2] - The company aims to expand its market presence through these clinical trials, which could lead to new therapeutic applications for its products [2] Company Developments - PharmAla has granted MAPS authorization to publicly post its Investigator's Brochure, enhancing access to research on MDMA for global researchers [3][4] - The company has issued options totaling 1,500,000 shares to various board members and officers, with a fixed exercise price of $0.105, vesting over a 12-month period [5][6][7] - PharmAla's CEO, Nicholas Kadysh, will participate in the Canadian Security Exchange's Summit on Responsible Investment, highlighting the company's commitment to responsible practices in the biotech sector [8] Company Overview - PharmAla Biotech focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company providing clinical-grade MDMA for patient treatments outside of clinical trials [9] - The company aims to alleviate the backlog of generic, clinical-grade MDMA and develop novel drugs, positioning itself as a regulatory-first organization in the psychedelics industry [9]